Price T Rowe Associates Inc. MD Lowers Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Price T Rowe Associates Inc. MD decreased its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 3.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,866,908 shares of the company's stock after selling 148,390 shares during the period. Price T Rowe Associates Inc. MD owned 4.47% of IDEAYA Biosciences worth $99,380,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. FMR LLC grew its holdings in shares of IDEAYA Biosciences by 2.6% during the 4th quarter. FMR LLC now owns 12,963,151 shares of the company's stock worth $333,153,000 after purchasing an additional 327,498 shares during the period. Vanguard Group Inc. lifted its holdings in shares of IDEAYA Biosciences by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 5,078,084 shares of the company's stock valued at $130,507,000 after acquiring an additional 282,936 shares in the last quarter. Geode Capital Management LLC boosted its position in IDEAYA Biosciences by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock worth $51,121,000 after purchasing an additional 43,226 shares during the period. Pictet Asset Management Holding SA boosted its position in IDEAYA Biosciences by 2.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,941,271 shares of the company's stock worth $49,891,000 after purchasing an additional 46,931 shares during the period. Finally, Candriam S.C.A. increased its holdings in IDEAYA Biosciences by 14.0% in the 4th quarter. Candriam S.C.A. now owns 1,071,825 shares of the company's stock valued at $27,546,000 after purchasing an additional 131,385 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Stephens reissued an "overweight" rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Royal Bank of Canada restated an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Price Performance

IDYA opened at $19.00 on Monday. The stock's 50 day moving average price is $18.00 and its 200 day moving average price is $23.37. The stock has a market cap of $1.66 billion, a P/E ratio of -5.76 and a beta of 0.51. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million. Equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.